Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 12, 2025
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
GlobeNewswire
·
May 12, 2025
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s …
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025
GlobeNewswire
·
May 12, 2025
Successful completion of €30 Million capital increase, with strong international demand and oversubscription Awarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector ( …
Herpesyl Under Review: Does This Herpes Supplement Really Work for Herpes Virus Symptoms?
GlobeNewswire
·
May 12, 2025
Aurora, Colorado, May 12, 2025 (GLOBE NEWSWIRE) -- Humans have long battled many serious diseases and conditions. Through the ages, humanity developed its knowledge of medicine and science. But even today, there are many diseases and sicknesses that are …
Best Weight Loss Supplements in USA 2025: Top Diet Pills That Actually Work Fast For Real Results - Wolfson Brands Ltd
GlobeNewswire
·
May 12, 2025
New York City, May 12, 2025 (GLOBE NEWSWIRE) -- Introduction: Best Weight Loss Supplements …
Alterity Therapeutics Prominently Featured at the International MSA Congress
GlobeNewswire
·
May 12, 2025
– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden …
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
GlobeNewswire
·
May 12, 2025
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain …
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire
·
May 12, 2025
TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central …
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire
·
May 12, 2025
Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company …
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
GlobeNewswire
·
May 12, 2025
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated …
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
GlobeNewswire
·
May 12, 2025
CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 …
Surgery Partners, Inc. Announces First Quarter 2025 Results; Reaffirms Full Year 2025 Guidance
GlobeNewswire
·
May 12, 2025
BRENTWOOD, Tenn., May 12, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2025. …
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GlobeNewswire
·
May 12, 2025
BETHESDA, Md., May 12, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, …
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences …
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
GlobeNewswire
·
May 12, 2025
Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer’s disease and HLHS, a rare pediatric disease and orphan-designated …
Curium receives marketing authorization in Switzerland for PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
GlobeNewswire
·
May 12, 2025
Swissmedic grants marketing authorization for PYLCLARI® in Switzerland b.e. Imaging is marketing authorization holder and has exclusive distribution rights for PYLCLARI® across Switzerland ZURICH, May 12, 2025 (GLOBE NEWSWIRE) -- Curium announced today …
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
GlobeNewswire
·
May 12, 2025
Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine could accelerate the pathway to functional eradication of …
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
GlobeNewswire
·
May 12, 2025
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a …
Optima Health plc - Full Year Trading Update
GlobeNewswire
·
May 12, 2025
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) …
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
GlobeNewswire
·
May 12, 2025
The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of schedule Teva launched two new programs to help people around the world access the medicines they need, …
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
May 12, 2025
Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected …